|
Time Technoplast To Set Up Medical Devices
Unit In Baddi
The Mumbai-based Time Technoplast, a technology based company, is setting a new
manufacturing facility of disposable medical devices at Thane near Baddi. It is
investing Rs 35 crore and the commercial production is expected to commerce from
October 2007.
Talking to Pharmabiz, Anil Jain, managing director, said, "We are already in the
manufacturing of healthcare products such as auto disable, blood collection
device and multi layer face masks. For the Baddi expansion we have already
purchased land with at a cost of Rs three crore. We are also investing around
Rs. 30 crore for the plant and machinery. The implementation of the project is
in advanced stage and is likely to go on stream by October 2007. We have already
set up marketing network for the domestic market.
The company has engaged in the manufacturing and sale of technology based
polymer products. Recently, company has entered into the healthcare business
segment by introducing auto disable syringe under the brand name Genex. The
company has subsequently launched auto collect blood disable syringe and
protective facemask. Protective facemask is basically used in the operation
theatre, clinical care department, and quarantine areas. It is highly advanced
mask which is not only protects the user in a bacterial air borne environment,
but also protect from the blood and body ward, fumigation and cleaning areas,
laboratories and clinics.
(Ref: Chronicle Pharmabiz dated May 17, 2007)
Marck Biosciences Plans Foray Into 20
Countries
After ramping up parenterals capacity at its facility in Kheda, Marck
Biosciences plans to apply for registration to market its products in South East
Asia, North and South America, Europe and Australia. The company, which has
presence in 40 countries, has plans to enter an additional 20 this year. The
foray in regulated markets is also aimed at achieving the target turnover of Rs
100 crore in 2007-08.
Marck, a manufacturer of parenterals for pharmaceutical companies, will launch a
range of products for international markets, including common solutions,
electrolyte replacements, antibiotic solutions, diuretics, anti-infective and
anti-fungal drug therapeutics. The company will set up its distribution network
in these regions by the end of 2007.
"We are focusing on a two-pronged strategy. We plan to expand our products in
international markets while exploring opportunities in outsourcing," says Marck
Biosciences MD Bhavesh Patel. Marck wants to emerge as the third largest
parenterals company in India and has invested Rs 72 crore at its manufacturing
facility in Gujarat to increase production to 230 million units of small volume
parenterals (SVP) and 61 million units of large volume parenterals (LVP). With
this infusion, the total investment in the Kheda facility would exceed Rs 125
crore. Marck's current production capacity is 65 million units for small volume
parenterals (SVP) and 29 million units for large volume parenterals (LVP).
Marck undertakes contract manufacturing of LVP and SVP for 48 of India's Top 50
pharma companies including Dr. Reddy's Torrent, Cadila, Themis, Zydus, Shreya,
Glenmak, Ranbaxy, Sun Pharma, FDC, Macleods, Intas and Lupin. The company's
international customer base includes several major internationsl drug firms.
Marck will launch a range of products for international markets, including
common solutions, electrolyte replacements, antibiotic solutions, diuretics,
anti-infective and anti-fungal drug therapeutics.
|
